Skip to main content
Clinical Trials/ISRCTN58905233
ISRCTN58905233Completed未知

Apolipoprotein B and low density lipoprotein size in type two diabetes: effect of atorvastatin and gemfibrozil

Hospital Sant Pau (Spain)0 sites44 target enrollmentStarted: April 24, 2007Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
44

Study Overview

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Men and women with type two diabetes, aged 35 to 75 years
  • 2. No treatment known to interfere with lipid metabolism (nonselective B-blockers, high dose diuretics, systemic steroids, lipid-lowering drugs) in the month preceding inclusion in the study
  • 3. Plasma Low Density Lipoprotein cholesterol (LDLc) greater than 100 mg/dl (2.6 mmol/litre), and triglycerides less than 400 mg/dl (4.51mmol/litre)

Exclusion Criteria

  • 1. Pregnant
  • 2. No reliable contraceptive method was used
  • 3. Serum creatinine more than 1.7 mg/dl (150 umol/litre)
  • 4. Hepatic dysfunction (transaminases greater than 1.5 times upper normal limit at inclusion)
  • 5. Creatine kinase more than three times the upper normal limit
  • 6. Acute or chronic disorders that might interfere with compliance

Investigators

Sponsor
Hospital Sant Pau (Spain)

Similar Trials

Apolipoprotein B and low density... | Clinical Trial